Top

Breast Cancer

Published in:

Open Access 01-05-2020 | Breast Cancer | Original Article

Growth pattern can be used as a new characteristic to predict malignancy in breast cancer

Authors: Bin Wang, Lizhe Zhu, Chenyang He, Minghui Tai, Can Zhou, Guanqun Ge, Huimin Zhang, Jianjun He, Ke Wang

Published in: Breast Cancer | Issue 3/2020

Abstract

Background

To date, anatomic tumor length is a key criterion for cancer staging and can be used to evaluate the effectiveness of therapies. This article describes growth pattern that can be used as a new characteristic to represent disease burden and tumor features and predict lymphatic metastasis.

Methods

Patients with breast cancer were included in this 10-year (1999–2008) hospital-based multicenter retrospective study. The pathologic length/height ratio was used to illustrate the correlation between tumor features, behaviors and treatments in breast malignancies. The most appropriate ratio was chosen based on the comprehensive evaluation of p value and changing trend of each characteristic.

Results

The sample consisted of 4211 women diagnosed with breast cancer. Among them, 2037 patients with complete pathologic length, width and height information were included in the final analysis. There were 2.34 ± 4.77 metastatic lymph nodes for spheroid tumors and 3.21 ± 5.82 for ellipsoid tumors when the cutoff point was 2. In addition, the proportion of ellipsoidal tumors gradually increased from 54.36 to 56.67% in the upper outer quadrant (UOQ) and from 6.7 to 9.03% in the central region with an increase in the cutoff point. The proportion of ER + PR + ellipsoid tumors significantly decreased from 50.1 to 45.35% and that of ER–PR ellipsoid tumors significantly increased from 32.73 to 36.24% with an increase in the cutoff point. Additionally, the best length/weight ratio to distinguish spheroid and ellipsoid tumors was 2.

Conclusion

This study described for the first time how growth pattern is correlated with tumor malignancy and how it influences the selection of therapeutic strategies for patients.

Available only for authorised users

Cardoso F, Harbeck N, Fallowfield L, Kyriakides S, Senkus E. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(suppl 7):vii1-19. https://doi.org/10.1093/annonc/mds232.CrossRef

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30. https://doi.org/10.3322/caac.21442.CrossRefPubMed

Nakasone ES, Hurvitz SA, Mccann KE. Harnessing the immune system in the battle against breast cancer. Drugs Context. 2018;7:212520. https://doi.org/10.7573/dic.212520.CrossRefPubMedPubMedCentral

Giuliano AE, Edge SB, Hortobagyi GN. Eighth edition of the AJCC cancer staging manual: breast cancer. Ann Surg Oncol. 2018;25(7):1783–5. https://doi.org/10.1245/s10434-018-6486-6.CrossRefPubMed

Wapnir IL, Wartenberg DE, Greco RS. Three dimensional staging of breast cancer. Breast Cancer Res Treat. 1996;41(1):15–9.CrossRefPubMed

Zhang BL, Sivasubramaniam PG, Zhang Q, Wang J, Zhang B, Gao JD, et al. Trends in radical surgical treatment methods for breast malignancies in China: a multicenter 10-year retrospective study. Oncologist. 2015;20:1036–43. https://doi.org/10.1634/theoncologist.2014-0281.CrossRefPubMedPubMedCentral

Moon HG, Kim N, Jeong S, Lee M, Moon H, Kim J, et al. The clinical significance and molecular features of the spatial tumor shapes in breast cancers. PLoS ONE. 2015;10(12):e0143811. https://doi.org/10.1371/journal.pone.0143811.CrossRefPubMedPubMedCentral

Uematsu T, Kasami M, Yuen S. Triple-negative breast cancer: correlation between MR imaging and pathologic findings. Radiology. 2009;250(3):638–47. https://doi.org/10.1148/radiol.2503081054.CrossRefPubMed

Leslie K, Gao SP, Berishaj M, Podsypanina K, Ho H, Ivashkiv L, et al. Differential interleukin-6/Stat3 signaling as a function of cellular context mediates Ras-induced transformation. Breast Cancer Res. 2010;12(5):R80. https://doi.org/10.1186/bcr2725.CrossRefPubMedPubMedCentral

10.

Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature. 2012;486(7403):395–9. https://doi.org/10.1038/nature10933.CrossRefPubMed

11.

Geyer FC, Weigelt B, Natrajan R, Lambros MB, de Biase D, Vatcheva R, et al. Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas. J Pathol. 2010;220(5):562–73. https://doi.org/10.1002/path.2675.CrossRefPubMed

12.

Martelotto LG, Ng CK, Piscuoglio S, Weigelt B, Reis-Filho JS. Breast Cancer Res. 2014;16(3):210. https://doi.org/10.1186/bcr3658.CrossRefPubMedPubMedCentral

13.

Navin N, Kendall J, Troge J, Andrews P, Rodgers L, McIndoo J, et al. Tumour evolution inferred by single-cell sequencing. Nature. 2011;472(7341):90–4. https://doi.org/10.1038/nature09807.CrossRefPubMedPubMedCentral

14.

Bedard PL, Hansen AR, Ratain MJ, Siu LL. Tumour heterogeneity in the clinic. Nature. 2013;501(7467):355–64. https://doi.org/10.1038/nature12627.CrossRefPubMedPubMedCentral

15.

Ichikawa Y, Nagashima Y, Morioka K, Akimoto K, Kojima Y, Ishikawa T, et al. Colorectal laterally spreading tumors show characteristic expression of cell polarity factors, including atypical protein kinase C lambda/iota, E-cadherin, beta-catenin and basement membrane component. Oncol Lett. 2014;8(3):977–84. https://doi.org/10.3892/ol.2014.2271.CrossRefPubMedPubMedCentral

16.

Thompson EW, Newgreen DF, Tarin D. Carcinoma invasion and metastasis: a role for epithelial-mesenchymal transition? Cancer Res. 2005;65(14):5991–5. https://doi.org/10.1158/0008-5472.CAN-05-0616(discussion 5995).CrossRefPubMed

17.

Hsu PK, Huang HC, Hsieh CC, Hsu HS, Wu YC, Huang MH, et al. Effect of formalin fixation on tumor size determination in stage I non-small cell lung cancer. Ann Thorac Surg. 2007;84(6):1825–9. https://doi.org/10.1016/j.athoracsur.2007.07.016.CrossRefPubMed

18.

Jiang YZ, Ma D, Suo C, Shi J, Xue M, Hu X, et al. Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies. Cancer Cell. 2019;35(428–440):e5. https://doi.org/10.1016/j.ccell.2019.02.001.CrossRef

Title: Growth pattern can be used as a new characteristic to predict malignancy in breast cancer
Authors: Bin Wang
Lizhe Zhu
Chenyang He
Minghui Tai
Can Zhou
Guanqun Ge
Huimin Zhang
Jianjun He
Ke Wang
Publication date: 01-05-2020
Publisher: Springer Japan
Keywords: Breast Cancer
Breast Cancer
Published in: Breast Cancer / Issue 3/2020
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI: https://doi.org/10.1007/s12282-019-01041-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2020

High-risk lesions diagnosed at MRI-guided vacuum-assisted breast biopsy: imaging characteristics, outcome of surgical excision or imaging follow-up

Patient-Reported Outcome Measures may optimize shared decision-making for cancer risk management in BRCA mutation carriers

Breast implant-associated anaplastic large-cell lymphoma: first case detected in a Japanese breast cancer patient

Comorbidity and polypharmacy in patients with breast cancer

Dose-dense adjuvant chemotherapy: a systematic review and meta-analysis of the Japanese Breast Cancer Society Clinical Practice Guideline, 2018 edition

Higher reconstruction failure and less patient-reported satisfaction after post mastectomy radiotherapy with immediate implant-based breast reconstruction compared to immediate autologous breast reconstruction

Keynote webinar | Spotlight on antibody–drug conjugates in cancer